Evidence map›Paper›PMID 34668743›Full record

ArticleMicrobiology spectrum2021

Repurposing of the Tamoxifen Metabolites to Treat Methicillin-Resistant Staphylococcus epidermidis and Vancomycin-Resistant Enterococcus faecalis Infections.

Andrea Miró-Canturri, Andrea Vila-Domínguez, Marta Caretero-Ledesma, Rafael Ayerbe-Algaba, Jerónimo Pachón, Manuel Enrique Jiménez-Mejías, Younes Smani

Open access · goldAbstract read
In one paragraph

Article in Microbiology spectrum, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 16 citations in OpenAlex.

  1. Tamoxifen inhibits histidine kinases ofMicrobiology spectrum · 2026
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Andrea Miró-Canturri *Clinical Unit of Infectious Diseases, Microbiology and Preventive Medicine, Virgen del Rocío University Hospital, Seville, Spain.
Andrea Vila-Domínguez *Clinical Unit of Infectious Diseases, Microbiology and Preventive Medicine, Virgen del Rocío University Hospital, Seville, Spain.
Marta Caretero-LedesmaClinical Unit of Infectious Diseases, Microbiology and Preventive Medicine, Virgen del Rocío University Hospital, Seville, Spain.
Rafael Ayerbe-AlgabaClinical Unit of Infectious Diseases, Microbiology and Preventive Medicine, Virgen del Rocío University Hospital, Seville, Spain.
Jerónimo PachónInstitute of Biomedicine of Sevillegrid.414816.e (IBiS), Virgen del Rocío University Hospital/CSIC/University of Seville, Seville, Spain.
Manuel Enrique Jiménez-MejíasClinical Unit of Infectious Diseases, Microbiology and Preventive Medicine, Virgen del Rocío University Hospital, Seville, Spain.
Younes SmaniClinical Unit of Infectious Diseases, Microbiology and Preventive Medicine, Virgen del Rocío University Hospital, Seville, Spain.ORCID 0000-0001-9302-8384
Instituto de Biomedicina de Sevilla · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Repurposing drugs provides a new approach to the fight against multidrug-resistant (MDR) bacteria. We have reported that three major tamoxifen metabolites,

Indexed as

Methicillin ResistanceAnti-Bacterial AgentsDrug RepositioningDrug Resistance, Multiple, BacterialEnterococcus faecalisGram-Positive Bacterial InfectionsHumansMicrobial Sensitivity TestsStaphylococcal InfectionsStaphylococcus epidermidisTamoxifenVancomycinAnti-Bacterial AgentsTamoxifenVancomycinantibacterialEnterococcusGram-positivemetaboliterepurposingStaphylococcustamoxifen

Identifiers

PMID34668743
PMCPMC8528103
OpenAlexW3206714145

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.